Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients

References

• Department of Health. 1998. Demographic and health survey [homepage available on the Internet]. c2010. Available from: http://www.doh.gov.za/facts/sadhs-f.html
   Google Scholar
• World Health Organization. 2006. The African regional health report. [homepage available on the Internet]. c2010 Available from: http://whqlibdoc.who.int/afro/2006/9290231033_rev_eng.pdf
   Google Scholar
• Bramlage P. Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. Vasc Health Risk Manag. 2009; 5: 213–224.
   PubMedGoogle Scholar
• Muszbek N, Brixner D, Benedict A, et al. The economic consequences of non-compliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008; 62(2): 338–351.
   PubMed Web of Science ®Google Scholar
• Mourad J-J. The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target. Vasc Health Risk Manag. 2008; 4(6): 1315–1325.
   PubMedGoogle Scholar
• Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. VascHealth Risk Manag. 2008; 4(3): 653–664.
   PubMedGoogle Scholar
• Ahmed N, Khaliq MA, Shah SH, Anwar W. Compliance to antihypertensive drugs, salt restriction, exercise and control of systemic hypertension in hypertensive patients at Abbottabad. J Ayub Med Coll Abbottabad. 2008; 20(2): 66–69.
   PubMedGoogle Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low-dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003; 326: 1427–1431.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Ruggenenti P, Remuzzi G. Managing hypertension in diabetic patients: focus on trandolapril/verapamil combination. Vasc Health Risk Manag. 2007; 3(4): 453–465.
   PubMedGoogle Scholar
• Waeber B, Ruilope LM. Amlodipine and valsartan as components of a rational and effective fixed-dose combination. VascHealth Risk Manag. 2009; 5: 165–174.
   PubMedGoogle Scholar
• Sureshkumar KK. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. Vasc Health Risk Manag. 2008; 4(6): 1205–1220.
   PubMedGoogle Scholar
• Rayner B. Combination therapy in hypertension. S Afr Fam Pract. 2007: 49(2): 22–24.
   Google Scholar
• Mengden T, Uen S, Bramlage P. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility. Vasc Health Risk Manag. 2009; 5: 1043–1058.
   PubMedGoogle Scholar
• Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment: a review. Cardiovasc Diabetol. 2009; 8: 18.
   PubMed Web of Science ®Google Scholar
• Thrall G, Lip GYH, Lane D. Compliance with pharmacological therapy in hypertension: can we do better, and how? J Hum Hypertens. 2004; 18: 595–597.
   PubMed Web of Science ®Google Scholar
• Lewanczuk R, Tobe SW. More medication, fewer pills: combination medications for the treatment of hypertension. Can J Cardiol. 2007; 23(7): 573–576.
   PubMed Web of Science ®Google Scholar
• Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vasc Health Risk Manag. 2006; 2(4): 401–409.
   PubMedGoogle Scholar
• Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag. 2009; 5: 411–427.
   PubMedGoogle Scholar
• No author. No renoprotection beyond RAS inhibitors? Medscape Cardiology. 2005; 9(1).
   Google Scholar
• Fogari R, Zoppi A, Mugellini A, Corradi L, et al. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr. 2009; 48(3): 401–401.
   PubMed Web of Science ®Google Scholar
• Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic therapy. BMC Family Practice. 2008; 9: 61.
   PubMed Web of Science ®Google Scholar
• Werner C, Baumhäkel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008; 97: 418–431.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del Vecchio L, Cavalli A. Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade. Nephron Clin Pract. 2009; 113: c286–c293.
   PubMed Web of Science ®Google Scholar
• Schindler C. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET. Ther Adv Cardiovasc Dis. 2008; 2(4): 233–248.
   PubMedGoogle Scholar
• Doulton TWR, MacGregor GA. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension. J Renin Angiotensin Aldosterone Syst. 2009; 10(4): 185–189.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003; 362: 777–781.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Östergren J, Swedberg K, et al. The Lancet. 2003; 362: 767–771.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Mazzotta G, et al. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag. 2008; 4(5): 971–981.
   PubMedGoogle Scholar
• Chunder R, Van der Merwe E, Noble J. Aliskiren: an oral renin inhibitor. Medifile. 2007; 21(8): 39–44.
   Google Scholar
• O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, and angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007; 49: 276.
   PubMed Web of Science ®Google Scholar
• Aliskiren. Micromedex® 2.0 (licensed subscription.)
   Google Scholar
• Whittaker C. Rational drug use: antihypertensive therapy. S Afr Pharm J. 2010; 77(10): 38–42.
   Google Scholar
• Böhm M, Werner C. Treating to protect: current cardiovascular treatment approaches and remaining needs. Medscape J Med. 2008; 10(Supp): S3.
   PubMedGoogle Scholar